Ser257

Site Information
ALLREGEsLEDLMKL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 468150

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 )
Disease tissue studied:	breast cancer ( 3 , 11 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , leukemia ( 12 , 15 , 16 , 26 ) , acute myelogenous leukemia ( 12 , 15 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 10 , 12 ) , acute megakaryoblastic leukemia (M7) ( 10 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 10 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 10 ) , acute myeloblastic leukemia, without maturation (M1) ( 10 ) , chronic myelogenous leukemia ( 26 ) , T cell leukemia ( 16 ) , lung cancer ( 2 , 6 ) , non-small cell lung adenocarcinoma ( 2 , 6 ) , lymphoma ( 4 ) , B cell lymphoma ( 10 ) , Burkitt's lymphoma ( 4 ) , non-Hodgkin's lymphoma ( 10 ) , follicular lymphoma ( 4 ) , mantle cell lymphoma ( 4 ) , ovarian cancer ( 3 ) , multiple myeloma ( 10 , 21 )
Relevant cell line - cell type - tissue:	293 (epithelial) [ADRB1 (human), no information, overexpresses human beta1-adrenergic (ß1AR- HEK293)] ( 27 ) , AML-193 (monocyte) ( 10 , 12 ) , B lymphocyte-blood ( 21 ) , BJAB (B lymphocyte) ( 4 ) , breast ( 1 , 3 ) , BT-20 (breast cell) ( 11 ) , CMK (megakaryoblast) ( 10 ) , CTS (myeloid) ( 10 ) , DOHH2 ('B lymphocyte, precursor') ( 10 ) , FL-18 (B lymphocyte) ( 4 ) , FL-318 (B lymphocyte) ( 4 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 13 ) , Flp-In T-Rex-293 (epithelial) ( 13 ) , GM00130 (B lymphocyte) ( 20 ) , HEL (erythroid) ( 10 , 12 ) , HUES-9 ('stem, embryonic') ( 19 ) , JEKO-1 (B lymphocyte) ( 4 ) , Jurkat (T lymphocyte) ( 7 , 17 , 18 , 24 , 25 ) , K562 (erythroid) ( 9 , 23 , 26 ) , Kasumi-1 (myeloid) ( 10 ) , KG-1 (myeloid) ( 10 , 15 ) , Kit225 (T lymphocyte) ( 16 ) , leukocyte-blood ( 22 ) , liver ( 5 ) , lung ( 6 ) , MV4-11 (macrophage) ( 10 ) , NCEB-1 (B lymphocyte) ( 4 ) , OCI-ly1 (B lymphocyte) ( 4 ) , OPM-2 (plasma cell) ( 10 ) , ovary ( 3 ) , P31/FUJ (erythroid) ( 10 ) , PC9 (pulmonary) ( 2 ) , PC9-IR (pulmonary) ( 2 ) , Raji (B lymphocyte) ( 4 ) , RAMOS (B lymphocyte) ( 4 ) , REC-1 (B lymphocyte) ( 4 ) , RL ('B lymphocyte, precursor') ( 10 ) , RPMI-8266 (plasma cell) ( 10 ) , SU-DHL-4 (B lymphocyte) ( 4 ) , SU-DHL-6 (B lymphocyte) ( 10 ) , U266 (plasma cell) ( 10 ) , UPN-1 (B lymphocyte) ( 4 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
3	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
4	Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42 24667141 Curated Info
5	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
6	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
7	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
8	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
9	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
10	Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37 23628362 Curated Info
11	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
12	Alcolea MP, et al. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 11, 453-66 22547687 Curated Info
13	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
14	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
15	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
16	Osinalde N, et al. (2011) Interleukin-2 signaling pathway analysis by quantitative phosphoproteomics. J Proteomics 75, 177-91 21722762 Curated Info
17	Mulhern D (2011) CST Curation Set: 12685; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
18	Mulhern D (2011) CST Curation Set: 12680; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
19	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
20	Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23 20164059 Curated Info
21	Ge F, et al. (2010) Phosphoproteomic analysis of primary human multiple myeloma cells. J Proteomics 73, 1381-90 20230923 Curated Info
22	Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32 20058876 Curated Info
23	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
24	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
25	Possemato A (2008) CST Curation Set: 4736; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
26	Stokes M (2008) CST Curation Set: 4390; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
27	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info